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Abstract: Gastroesophageal reflux disease (GERD) is a chronic, recurrent disease that affects 
nearly 19 million people in the US. The mainstay of therapy for GERD is acid suppression. 
Proton pump inhibitors (PPIs) are the most effective medication for both initial treatment and 
maintenance therapy of GERD. Pantoprazole, a first-generation PPI, was approved by the FDA 
in 2000 for the treatment of erosive esophagitis associated with GERD. It has been used in more 
than 100 different countries worldwide. It is one of the few PPIs available in multiple forms: 
a delayed-release oral capsule, oral suspension, and intravenous. Pantoprazole been shown to 
improve acid reflux-related symptoms, heal esophagitis, and improve health-related quality 
of life more effectively than histamine-2 receptor antagonists. Evaluated in over 100 clinical 
trials, pantoprazole has an excellent safety profile, is as efficacious as other PPIs, and has a low 
incidence of drug interactions. It has also been shown to be safe and effective in special patient 
populations, such as the elderly and those with renal or moderate liver disease.
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Introduction to gastroesophageal reflux disease
In 2006, the Montreal Consensus Group provided a global evidence-based definition 
of gastroesophageal reflux disease (GERD) as “a condition which develops when the 
reflux of stomach contents [into the esophagus] causes troublesome symptoms and/or 
complications”.1 It is a chronic, often relapsing disease that if not treated appropriately 
can lead to further complications including esophageal ulcers, stricture formation, 
obstruction, Barrett’s, and esophageal cancer. In addition, GERD can potentially 
lead to extra-esophageal complications, such as worsening asthma-like symptoms 
and chest pain.2 Reports indicate that GERD affects an estimated 19 million people 
in the US alone. This figure is likely to be an under-representation as many patients 
are misdiagnosed and subsequently not appropriately treated.3 Patients with GERD 
report a worse quality of life than those with diabetes, hypertension, mild heart failure, 
and angina.4–6
Based on the 2005 practice guidelines, the mainstay of therapy for GERD is acid 
suppression.7 Over the last 30 years, there has been an influx of various agents aimed at 
adequately controlling acid secretion and subsequently the symptoms of GERD. Since 
the discovery of the proton pump in the early 1970s and the subsequent development 
of proton pump inhibitors (PPIs); the mechanism by which GERD is treated has been 
revolutionized.8 In 1989, omeprazole entered the market as the first PPI to treat acid 
reflux.9 Then in 2000, pantoprazole became the fourth PPI marketed in the US and the 
first PPI to be available in both oral and intravenous (iv) forms.10Clinical and Experimental Gastroenterology 2010:3 12
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Introduction of pantoprazole  
and its indications
After 8 years of research, Wyeth Pharmaceuticals introduced 
pantoprazole in April, 1985.8 By 1994, pantoprazole was 
already in use throughout Europe but Food and Drug 
Administration (FDA) approval for use in the US did not occur 
until 20008 (Table 1). Initially, pantoprazole was approved for 
treatment and maintenance of erosive esophagitis (40 mg/day 
for 8 to 16 weeks).9 Later in 2001, pantoprazole iv was 
approved for short-term treatment (7 to 10 days) of GERD 
patients and a history of erosive esophagitis (40 mg/day) 
who are unable to tolerate oral pantoprazole.11 Since then, 
the indications for pantoprazole have expanded to include a 
variety of gastric acid-related diseases, including peptic ulcer 
disease (PUD), NSAID-induced ulcer prevention, Zollinger–
Ellison syndrome, and adjunctive therapy for Helicobacter 
pylori eradication.9
Structure and physiology  
of pantoprazole
Pantoprazole is a membrane permeable substituted 
benzimidazole derivative that decreases gastric acid secretion 
by irreversibly inhibiting the H+/K+-ATPase located within 
gastric parietal cells.10,12,13 It has high tissue selectivity for the 
canalicular lumen of the parietal cell, which has a pH of 1.14 
Like other PPIs, it is a weakly basic prodrug that accumulates 
within this highly acidic environment and becomes rapidly 
activated into a cationic sulfonamide.10,13,15 The protonated 
form then covalently binds to specific cysteine residues on 
the H+/K+ ATPase enzyme, thus irreversibly inactivating 
the pump. Compared to other PPIs, pantoprazole is less 
likely to become activated in neutral to moderately acidic 
environment s (pH 3 to 5). The narrow pH window prevents 
pantoprazole from acting at nontarget areas in the body, thus 
reducing adverse effects.10,14,16 In vitro studies have shown 
that pantoprazole may actually have a longer duration of 
action than other PPIs because it is the only PPI to bind both 
cysteine 813 and cysteine 882, the more distal residue of the 
proton pump.14 Theoretically, the distal site is less accessible 
to agents such as glutathione or dithiothreitol that potentially 
reverse proton pump inhibition.17
Pharmacokinetics of pantoprazole
Pantoprazole follows dose linear pharmacokinetics. Oral 
pantoprazole has a bioavailability of 77% and its absorption 
is not affected by food or antacids.10 It is ultimately absorbed 
in the small bowel, resulting in a maximum serum concentra-
tion 2 to 3 hours postingestion.18 Therefore, pantoprazole is 
most effective when given prior to meals so it reaches peak 
serum levels when the maximum number of proton pumps 
are activated postprandially.11 Unlike other PPIs, the serum 
concentration of pantoprazole is not dose-dependent; serum 
concentration after 1 dose is similar to that after multiple 
doses.19 Pantoprazole is completely metabolized via the 
hepatic cytochrome P450 system by CYP2C19 and CYP3A4, 
and up to 80% of the inactive metabolites are eliminated 
via renal exctretion.11,12 The metabolism of pantoprazole is 
independent of the route of administration, with a half-life 
of approximately 1.1 hours.10 However in patients with a 
mutation in the gene encoding the CYP2C19 enzyme, the 
half-life may be up to 3 hours.20
Efficacy and current findings  
of pantoprazole
Numerous multicenter randomized control studies have shown 
pantoprazole to be more efficacious than histamine-2 receptor 
antagonists (H2RAs) as the first-line drug for both treatment 
and maintenance therapy of erosive esophagitis associated 
with GERD.10,21–24 Pantoprazole 40 mg/day for 4 to 8 weeks 
is the optimal regimen for the treatment of moderate to severe 
GERD.25 Patients taking oral pantoprazole 40 mg/day had 
higher endoscopically confirmed healing rates at 4 weeks 
and 8 weeks, respectively, when compared with patients 
taking ranitidine 150 mg twice daily (54.0% to 95.1% vs 
20.0% to 66.7% and 75.0% to 98.8% vs 41.0% to 77.4%, 
P  0.001) or nitzatadine (79% vs 44%, P  0.001).10,19,22,26,27 
Similarly, patients taking pantoprazole 40 mg/day had higher 
endoscopic remission rates than rantidine 150 mg twice daily 
Table 1 FDA-approved indications for pantoprazole in the treatment of gastroesophageal reflux disease (GERD) in the US
Year Indication Dosage Route Duration
2000 Healing of erosive esophagitis 40 mg daily po capsule 8–16 weeks
2000 Maintenance of erosive esophagitis 40 mg daily po capsule Continuous
2001 Erosive esophagitis with GErD unable to tolerate po 40 mg daily iv 7–10 days
2007 Erosive esophagitis with GErD unable to tolerate po capsule 40 mg daily po suspension Continuous
Abbreviations: FAD, US Food and Drug Administration; iv, intravenous; po, by mouth.Clinical and Experimental Gastroenterology 2010:3 13
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(78.0% to 82% vs 21.0% to 33%, P  0.001) for maintenance 
therapy at 12 months.14,28
When compared to other PPIs, pantoprazole has similarly 
efficacy in both the initial treatment and maintenance therapy 
of GERD. A double-blind, randomized, control study showed 
that pantoprazole 40 mg/day and esomeprazole 40 mg/day 
produce equivalent intraesophageal pH profiles and both 
similarly decrease esophageal acidity to normal levels 6 to 
24 hours postingestion.29 Endoscopic healing rates at 4 weeks 
and 8 weeks show no statistically significant differences when 
comparing pantoprazole 40 mg/day to omeprazole 20 mg/day, 
omeprazole multiple unit pellet system 40 mg/day, and lanso-
prazole 30 mg/day.30–32 For maintenance therapy, pantoprazole 
20 mg/day is equivalent to esomeprazole 20 mg/day for 
both endoscopic healing rates and symptom control at both 
6 months and 12 months.33,34
Pantoprazole has been shown to improve health-related 
quality of life more effectively than H2RAs and with similar 
efficacy to other PPIs.2,5,6,35 Patients taking pantoprazole 
40 mg/day had a greater percentage of symptom-free days 
at 12 months compared to patients taking ranitidine 150 mg 
twice daily (83% vs 58%, P  0.001).14 A similar study 
found pantoprazole to provide greater symptom relief than 
famotidine.23 Although the efficacy seems to be relatively 
similar when comparing pantoprazole to other PPIs, limited 
data indicate that pantoprazole has a faster onset of symptom 
relief in patients with mild GERD.36,37 Similarly, in a study 
comparing pantoprazole 40 mg/day to esomeprazole 
40 mg/day, patients treated with pantoprazole experienced 
less symptom relapse (51% vs 61%, P  0.05) and fewer 
symptomatic episodes (56% vs 71%, P  0.01) at one week 
post treatment than the esomeprazole group.38 Pantoprazole 
40 mg/day has also been shown to provide more effective 
control of night-time symptoms of GERD compared to 
esomeprazole 40 mg/day.39 In the above studies, symptoms 
evaluated include heartburn, odynophagia, dysphagia, and 
acid regurgitation. Pantoprazole has positive patient satisfac-
tion rates in trials involving patient questionnaires aimed at 
evaluating health-related quality of life such as ReQuest, 
GERDyzer, and the GERD symptom frequency question-
naire (GSFQ).35,40,41
Since pantoprazole is effective in controlling symptoms 
related to GERD and improving health-related quality 
of life, interest has arisen in using pantoprazole on an 
as-needed basis, rather than every-day doses. This concept 
is known as on-demand therapy. Although not currently 
FDA approved, on-demand therapy with pantoprazole 
has been shown to be effective in the treatment of patients 
with mild GERD in randomized control studies.42–44 In one 
study, patients with GERD were initially treated for 4 weeks 
with pantoprazole 20 mg/day, and subsequently received 
pantoprazole 20 mg/day or 40 mg/day for the following 
6 months as needed for recurrent symptoms. A score was 
then calculated based on the patient’s perceived average 
daily symptom load. At 6 months, the mean symptom load 
scores were significantly lower in the treatment groups than 
in the placebo group (pantoprazole 20 mg: 2.91; pantopra-
zole 40 mg: 2.71; placebo: 3.93) (P  0.0001).44 There was 
no statistical difference between the two dosage groups of 
pantoprazole. Similarly, a study (n = 236) of on-demand 
therapy for mild GERD comparing pantoprazole 20 mg to 
esomeprazole 20 mg revealed heartburn symptoms to be less 
severe in the pantoprazole group.42,44
Special administration 
considerations of pantoprazole
Conventional pantoprazole is formulated as an enteric-coated, 
delayed-release tablet. However, pantoprazole is one of the 
few PPIs available in both iv and oral suspension form for 
the treatment of GERD in patients who are unable to tolerate 
the delayed-release capsule form.11 Pantoprazole iv, which 
was approved in 2001 by the FDA, has equivalent efficacy 
to oral pantoprazole in its ability to suppress gastric acid 
output.45 In 2007, the FDA also approved pantoprazole to 
be available in oral suspension form for the treatment of 
erosive esophagitis in patients unable to swallow capsules. 
Although studies are limited, a recent multicenter randomized 
control study (N = 60) showed oral suspension pantoprazole 
to provide similar efficacy to oral capsules in suppressing 
gastric acid output.46
Safety and tolerability  
of pantoprazole
Short- and long-term clinical trials show oral pantoprazole 
40 to 120 mg/day to have an excellent safety profile.47 
Studies ranging from 8 weeks to 4 years have shown the 
incidence of adverse effects to be as low as 1% to 3%.47,48 
The most commonly reported side effects include diarrhea 
(2%), headaches (2%), nausea (1%), and constipation (1%). 
As with most PPIs, diarrhea is the most prevalent of these side 
effects.11 Isolated case reports have associated pantoprazole 
use with thrombocytopenia and acute interstitial nephritis.49–51 
Recently, long-term PPI use has been shown to have increased 
class-associated incidence for hip fractures; however, no 
individual reports are available for pantoprazole.52 Adverse 
side effects reported in patients with GERD who receive iv Clinical and Experimental Gastroenterology 2010:3 14
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pantoprazole include headache, nausea, dizziness, flushing, 
and pain at the site of injection; however, data on tolerability 
in this subset of patients are limited.53
Randomized, controlled, double-blind control trials in 
patients with GERD have shown that oral pantoprazole 
40 mg/day has a comparable tolerability profile to oral 
omeprazole 20 mg/day and lansoprazole 30 mg/day after 
8 weeks of therapy.54,55 In addition, oral pantoprazole 
40 mg/day has similar tolerability comparing to H2RAs, 
such as ranitidine 300 mg/day and famotidine 40 mg/day.56 
Like other PPIs, pantoprazole can cause elevated gastrin 
levels; however, no data have been published indicating a 
correlation between elevated gastrin levels and an increased 
risk for cancer.2,10
There have been a few reported significant adverse drug 
interactions between pantoprazole and other medications 
metabolized through the CYP450 system. Unlike omepra-
zole, which recently has been shown to decrease the antiplate-
let activity of clopidogrel, and which is also metabolized by 
CYP450, pantoprazole does not affect clopidogrel efficacy.57 
Given pantoprazole’s lower incidence for drug interactions 
compared to other PPIs, it is both safe and effective for 
long-term treatment of acid-related disorders in the elderly, 
a population at increased risk for adverse interactions due 
to medications. In addition, older patients have a higher 
incidence of developing severe esophagitis and its complica-
tions. Their relapse rate is also higher than that of younger 
patients if therapy with a PPI is not continued. Pantoprazole 
is also well tolerated in patients with renal failure and mild 
to moderate liver dysfunction (CHILDS class A/B). However, 
it has a relative contraindication in patients with severe liver 
disease.11
Conclusion and future targets
The data reviewed here show that pantoprazole is both 
safe and effective in the initial treatment and maintenance 
therapy for the management of erosive and nonerosive 
GERD. It has superior efficacy to H2RAs and has relatively 
equivalent efficacy compared to other PPIs. It is effica-
cious for both esophageal healing and relief of symptoms 
associated with GERD. Pantoprazole’s favorable side 
effect profile and low incidence of drug–drug interactions 
make it ideal for using in special patient populations, such 
as the elderly and those with renal failure and moderate 
liver dysfunction. Future targets for study include more 
extensive trials on the use of continuous iv pantoprazole 
in the treatment of severe erosive esophagitis and long-
term studies on the safety and efficacy of oral suspension 
formulation.58 In addition, expanding FDA approval for 
the use of pantoprazole in children and adolescents is cur-
rently being considered.59,60
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